A new Alzheimer's drug called PMN310 is taking a different approach to treating the disease. Rather than clearing large amyloid plaques like existing approved therapies, it targets smaller toxic protein fragments called oligomers believed to cause early damage. Six-month interim data from 136 participants showed no cases of dangerous brain swelling (ARIA-E), a serious side effect common with current treatments. Early biomarker signals also moved in a favorable direction. Notably, the trial included a high proportion of APOE4 gene carriers — the group most vulnerable to ARIA with existing drugs — yet still showed no swelling events. The trial remains blinded, so final conclusions await the 12-month readout expected in early 2027.
